Safety of prolonged high-dose levofloxacin therapy for bone infections

Journal of Chemotherapy

Volumn 19, Issue 6, 2007, Pages 688-693

  Senneville, Eric ^a   Poissy, J ^a   Legout, L ^a   Dehecq, C ^a   Loiez C ^b   Valette, M ^a   Beltrand, E ^a   Caillaux, M ^a   Mouton, Y ^a   Migaud, H ^b   Yazdanpanah, Y ^a  

^a Dron Hospital   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Adverse events; Bone infections; Dosing; Levofloxacin

Indexed keywords

CLINDAMYCIN; DOXYCYCLINE; FOSFOMYCIN; FUSIDIC ACID; LEVOFLOXACIN; LINEZOLID; PRISTINAMYCIN; RIFAMPICIN;

ADULT; AGED; ARTICLE; BONE INFECTION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS; HUMAN; HUMAN TISSUE; JOINT ASPIRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MYALGIA; TENDINITIS; THRUSH; TREATMENT DURATION;

EID: 38949128651     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2007.19.6.688     Document Type: Article

References (24)

1. Lew DP, Waldvogel FA. Osteomyelitis. N Engl J Med 1997; 336: 999-1007.
2. Wimer SM, Schoonover L, Garrison MW. Levofloxacin: a therapeutic review. Clin Ther 1998; 20, 1049-70.
3. Rimmelé T, Boselli E, Breilh D, et al. Diffusion of levofloxacin into bone and synovial tissues. J Antimicrob Chemother 2004; 53, 533-5.
4. Oberdorfer K, Swoboda S, Hamann A et al. Tissue and serum levofloxacin concentrations in diabetic foot infection patients. J Antimicrob Chemother 2004; 54: 836-9.
5. Chow AT, Chen A, Lattime H et al. Penetration of levofloxacin into skin tissue after oral administration of multiple 750 mg once-daily doses. J Clin Pharmacol Ther 2002; 27: 143-50.
6. Preston SL, Drusano GL, Berman AL et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279: 125-9.
7. Wright DH, Brown GH, Peterson ML et al. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 2000; 46: 669-83.
8. Norden CW. Experimental chronic staphylococcal osteomyelitis in rabbits: treatment with rifampin alone and in combination with other antimicrobial agents. Rev Infect Dis 1983; 5 Suppl 1: 491-94.
9. Wehrli W. Rifampin: mechanisms of action and resistance. Rev Infect Dis 1983; 5 Suppl 1: 407-11.
10. Zavasky DM, Sande MA. Reconsideration of rifampin: a unique drug for a unique infection. JAMA 1998; 279: 1575-7.
11. Shirtliff ME, Calhoun JH, Mader JT. Comparative evaluation of oral levofloxacin and parenteral nafcillin in the treatment of experimental methicillin-susceptible Staphylococcus aureus osteomyelitis in rabbits. J Antimicrob Chemother 2001; 48, 253-8
12. Murillo O, Doménech A, Garcia A, Tubau F, Cabellos C, Gudiol F, Ariza J. Efficacy of high-doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible S. aureus. Antimicrob Agents Chemother 2006; 50: 4011-7.
13. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic joint infections. N Engl J Med 2004; 351:1645-54.
14. Viale P, Pea F, Scudeller L et al. Pharmacokinetic and pharmacodynamic aspects of high dose oral levofloxacin therapy for bone infections. Clin Microb Infect 2005; 11 Suppl2: 653.
15. Greenberg RN, Newman MT, Shariaty S et al. Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis. Antimicrob Agents Chemother 2000; 44: 164-6.
16. Azanza JR, Cardenas E, Munoz MJ et al. Clinical experience with long-term treatment of osteoarticular infections. Rev Med Univ Navarra 2002; 46: 23-7.
17. Ortega M, Soriano A, Garcia S, et al. Tolerability and safety of levofloxacin long-term treatment. Rev Esp Quimioter 2000; 13 :263-6.
18. Zimmerli W, Widmer AF, Blatter M, et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections. JAMA 1998; 279: 1537-41.
19. Rissing JP. Antimicrobial therapy for chronic osteomyelitis in adults: role of the quinolones. Clin Infect Dis 1997; 25: 1327-33.
20. Kang SL, Ryback MJ, McGrath BJ et al. Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and-resistant Staphylococcus aureus in an in vitro infection model. Antimicrob Agents Chemother 1994; 38: 2702-9.
21. Humbert G., Brumpt I, Montay G, Le Liboux A, Borsa-Lebas F, Moore N. Influence of rifampin on the pharmacokinetics of pefloxacin. Clin Pharmacol Ther. 1991; 50: 682-7.
22. Chow AT, Fowler C, Williams RR et al. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob Agents Chemother 2001; 45: 2122-5.
23. Chien S-C, Wong FA, Fowler CL et al. Double-bind evaluation of the safety and pharmacokinetics of multiple once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Antimicrob Agents Chemother 1998 ; 42: 885-8.
24. Graham DR, Talan DA, Nichols RL et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clin Infect Dis 2002; 35:381-9.